{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:15:50Z","timestamp":1790712950904,"version":"4.1.0"},"reference-count":42,"publisher":"Informa UK Limited","issue":"28","funder":[{"name":"Bristol-Myers Squibb Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2217\/fon-2020-0351","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T13:47:41Z","timestamp":1596030461000},"page":"2165-2175","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-4143","authenticated-orcid":false,"given":"Nikhil I","family":"Khushalani","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center,\rTampa,\rFL33612,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-0244","authenticated-orcid":false,"given":"Adi","family":"Diab","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, Division of Cancer Medicine,MD Anderson Cancer Center,\rHouston,\rTX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale IRCCS,\rNapoli,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-9523","authenticated-orcid":false,"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Royal Marsden Hospital NHS Foundation Trust,\rLondon,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, The University of Melbourne,\rMelbourne,\rVictoria,\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale\u2013New Haven Hospital,\rNew Haven,\rCT06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry B","family":"Koon","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\rPrinceton,\rNJ08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Jarkowski","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\rPrinceton,\rNJ08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-3185","authenticated-orcid":false,"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\rPrinceton,\rNJ08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8774-2095","authenticated-orcid":false,"given":"Paul","family":"Statkevich","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\rPrinceton,\rNJ08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Geese","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb,\rPrinceton,\rNJ08543, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Royal North Shore & Mater Hospital,\rSt Leonards,\rNSW,\rAustralia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.021"},{"key":"e_1_3_5_4_1","unstructured":"OPDIVO\u00ae (nivolumab) package insert. Bristol Myers Squibb Company NJ USA (Revised March 2020). https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"e_1_3_5_5_1","unstructured":"European Medicines Agency . Summary of product characteristics: OPDIVO\u00ae (nivolumab) Bristol Myers Squibb House (2020). www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf"},{"key":"e_1_3_5_6_1","unstructured":"KEYTRUDA\u00ae (pembrolizumab) package insert. Merck & Co. Inc. NJ USA (2020). www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"e_1_3_5_7_1","unstructured":"European Medicines Agency . Summary of product characteristics: KEYTRUDA\u00ae (pembrolizumab). Merck Sharp & Dohme B.V. (2019). www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_5_8_1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in oncology \u2013 cutaneous melanoma version 3.2019 (2019). www.nccn.org\/professionals\/physician_gls\/default.aspx [login necessary]."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_3_5_10_1","volume-title":"International Congress of the Society for Melanoma Research (SMR).","author":"Robert C","year":"2019","unstructured":"Robert C , LongGV, BradyBet al. Five-year survival outcomes in patients with BRAF wild-type advanced melanoma who received nivolumab monotherapy in the Phase 3 CheckMate 066 study. Abstract presented at: International Congress of the Society for Melanoma Research (SMR).UT, USA, (20\u201323 November, 2019)."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7040870"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2016.08.01"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14471-1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y"},{"key":"e_1_3_5_22_1","unstructured":"Proleukin\u00ae (aldesleukin) package insert. Prometheus Laboratories Inc. CA USA (2018). www.proleukin.com\/downloads\/PR001I_Package%20Insert%20Clean.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1910-x"},{"key":"e_1_3_5_24_1","volume-title":"Society for Immunotherapy of Cancer (SITC) Annual Meeting.","author":"Bentebibel S","year":"2017","unstructured":"Bentebibel S , BernatchezC, HaymakerCet al. The novel IL-2 cytokine immune agonist NKTR-214 harnesses the adaptive and innate immune system for the treatment of solid cancers. Presented at: Society for Immunotherapy of Cancer (SITC) Annual Meeting.MD, USA, Poster P-77 (8\u201312 November 2017)."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1631"},{"key":"e_1_3_5_26_1","volume-title":"Society for Immunotherapy of Cancer (SITC) Annual Meeting.","author":"Diab A","year":"2018","unstructured":"Diab A , TykodiS, CurtiBet al. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma. Society for Immunotherapy of Cancer (SITC) Annual Meeting.DC, USA, 7\u201311 November 2018."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87324"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1510"},{"key":"e_1_3_5_31_1","volume-title":"American Society of Clinical Oncology (ASCO) Annual Meeting.","author":"Charych DH","year":"2016","unstructured":"Charych DH , RubasW, DixitVet al. Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor. American Society of Clinical Oncology (ASCO) Annual Meeting.IL, USA, 3\u20137 June 2016 (Abstract 11545)."},{"key":"e_1_3_5_32_1","unstructured":"ClinicalTrials.org . A study of a CD122-biased cytokine (NKTR-214) in combination with anti-PD-1 (pembrolizumab) in patients with select advanced or metastatic solid tumors (PROPEL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03138889"},{"key":"e_1_3_5_33_1","unstructured":"ClinicalTrials.org . A dose escalation and cohort expansion study of NKTR-214 in combination with nivolumab another anti-cancer therapies in patients with select advanced solid tumors (PIVOT-02). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02983045"},{"issue":"1","key":"e_1_3_5_34_1","first-page":"283","article-title":"Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the Phase I\/II PIVOT-02 study","volume":"7","author":"Diab A","year":"2019","unstructured":"Diab A , PuzanovI, MaioMet al. Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the Phase I\/II PIVOT-02 study. J. Immunother. Cancer7(Suppl.1), 283 (Abstract 035) (2019).","journal-title":"J. Immunother. Cancer"},{"key":"e_1_3_5_35_1","volume-title":"American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).","author":"Hurwitz ME","year":"2017","unstructured":"Hurwitz ME , DiabA, BernatchezCet al. A novel immune agonist, NKTR-214, increases the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).FL, USA, Poster 454 (16\u201318 February 2017)."},{"key":"e_1_3_5_36_1","unstructured":"Bristol Myers Squibb . Press release: Nektar Therapeutics and Bristol-Myers Squibb announce U.S. FDA breakthrough therapy designation for bempegaldesleukin (NKTR-214) in combination with Opdivo\u00ae (nivolumab) for the treatment of patients with untreated advanced melanoma. (2019). https:\/\/news.bms.com\/press-release\/partnering-news\/nektar-therapeutics-and-bristol-myers-squibb-announce-us-fda-breakthro"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0493"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"e_1_3_5_40_1","unstructured":"ClinicalTrials.gov . A study of NKTR-214 Combined with nivolumab vs nivolumab alone in participants with previously untreated inoperable or metastatic melanoma (PIVOT IO 001). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635983"},{"key":"e_1_3_5_41_1","unstructured":"ClinicalTrials.gov . A study of bempegaldesleukin (NKTR-214: BEMPEG) in combination with nivolumab compared with the investigator\u2019s choice of a tyrosine kinase inhibitor (TKI) therapy (either sunitinib or cabozantinib monotherapy) for advanced metastatic renal cell carcinoma (RCC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03729245"},{"key":"e_1_3_5_42_1","unstructured":"ClinicalTrials.gov . Single-arm study of bempegaldesleukin (NKTR-214) plus nivolumab in cisplatin ineligible patients who have locally advanced or metastatic urothelial cancer (PIVOT-10). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03785925"},{"key":"e_1_3_5_43_1","unstructured":"ClinicalTrials.gov . A study of nivolumab plus NKTR-214 vs nivolumab alone vs standard of care in participants with bladder cancer that has invaded the muscle wall of the bladder and who cannot get cisplatin a type of medicine given to treat bladder cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04209114"},{"key":"e_1_3_5_44_1","unstructured":"ClinicalTrials.gov . A Phase III randomized open-label study to compare adjuvant immunotherapy of bempegaldesleukin combined with nivolumab versus nivolumab after complete resection of melanoma in patients at high risk for recurrence (PIVOT-12). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04410445"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:10Z","timestamp":1719124930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":42,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.2217\/fon-2020-0351"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0351","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}